EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In silico investigation of the molecular interactions between mesocarb and the dopamine transporter

Natalia V. Petukhova, Dmitrii S. Bug, Ilya A. Cherepanov, Ilya M. Sukhanov

Psychopharmacology and Addiction Biology · 21.09.2026 · 17 (2) · 107-118

DOI: 10.17816/phbn712959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology and Addiction Biology, online erschienen am 21.09.2026. Verfasst von Natalia V. Petukhova und 3 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dopaminergic dysfunction is one of the elements of the pathogenesis of numerous psychiatric and neurological disorders, including Parkinson's disease, chemical addictions, depression, and attention deficit hyperactivity disorder. Dopamine transporter inhibitors have been used for decades in the treatment of such conditions, with particular interest in inhibitors that combine clinical efficacy with a low risk of addiction. One of the promising candidates is mesocarb—an original psychostimulant developed in 1971 in the USSR. However, the molecular mechanism of its stimulating action is currently insufficiently studied. AIM: To characterize the interaction of mesocarb with the dopamine transporter at the molecular level in silico. METHODS: Molecular dynamics simulation (500 ns), docking using the Induced-Fit protocol, and in silico site-directed mutagenesis were performed. RESULTS: The results indicate that mesocarb stably binds to the orthosteric site S1/S2 of the dopamine transporter, exhibits higher affinity for the transporter in the inward-open conformation, preserves the hydrogen bond Asp79–Tyr156, and demonstrates an interaction profile similar to modafinilφ. CONCLUSION: The characteristics obtained in silico of the molecular interaction of mesocarb with the dopamine transporter allow us to suggest that this molecule belongs to “atypical” modafinil-like inhibitors of the dopamine transporter.

Zitieren

APA

Petukhova, N. V., Bug, D. S., Cherepanov, I. A., & Sukhanov, I. M. (2026). In silico investigation of the molecular interactions between mesocarb and the dopamine transporter. Psychopharmacology and Addiction Biology, 17(2), 107-118. https://doi.org/10.17816/phbn712959

Vancouver

Petukhova NV, Bug DS, Cherepanov IA, Sukhanov IM. In silico investigation of the molecular interactions between mesocarb and the dopamine transporter. Psychopharmacology and Addiction Biology. 2026;17(2):107-118. doi:10.17816/phbn712959

BibTeX
@article{Petukhova2026,
  author = {Petukhova, Natalia V. and Bug, Dmitrii S. and Cherepanov, Ilya A. and Sukhanov, Ilya M.},
  title = {In silico investigation of the molecular interactions between mesocarb and the dopamine transporter},
  journal = {Psychopharmacology and Addiction Biology},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {107--118},
  doi = {10.17816/phbn712959}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche